Scancell Share Discussion Threads

[rogerbridge] 30/1/2024 20:51

A good write up Marcus. Well done.

[rogerbridge] 30/1/2024 20:50

Whoops, I have just seen the excellent write up from Marcus on the other thread.

[rogerbridge] 30/1/2024 20:47

A very interesting presentation this afternoon. It sounded as though all interested companies wanted exclusivity.

[bermudashorts] 30/1/2024 19:41

Plasbryn,

Try this link - is working for me.

[plasybryn] 30/1/2024 19:30

Is the presentation available to hear?

[miavoce] 30/1/2024 18:44

I'm hoping we see 3 deals this year, one in Q2, one in Q3 and one in Q4. seems reasonable given what Lindy said about the number of parties involved, the focus on ADC's and the vying for exclusivity. Clearly a lot of genuine interest.

[small crow] 30/1/2024 18:05

Looking good.

[marcusl2] 30/1/2024 16:35

Exciting stuff Connello.

[connello] 30/1/2024 15:14

Excellent Summary Marcus.

[nigelpm] 30/1/2024 15:08

likely to be 1 possibly two deals similar to the Genmab one within 12 months - would push out further funding to early 2026 at least.

[marcusl2] 30/1/2024 15:08

They are getting a lot of interest in the antibodies. 5 Pharma companies are in discussion " In fact, they are currently fighting for exclusivity" LD

So I wonder what that means?

A lot of interest in Scib-1/iScib+ but they want the data on 43 patients. Then maybe a deal or Scancell will wait and get more money after PII.

Trial will be in the USA and UK. Not EU atm because they charge £100k per patients for the CPIs.

Scib has been melting big bulky tumours in some of the patients.

New patent filed for Scib plus CPI

More centres coming on.

Modi-1 will be moving into the 1st line with Doublet in Renal Cell Carcinoma. Exciting.

I can see huge interest from big pharma using doublet CPIs in many cancers. They will want to use our vaccines in combination.

Probably two deals for the antibodies within 12 months (hopefully sooner)

[inanaco] 30/1/2024 15:05

well with 5 deals on the go .......

back to chill time "buy"

get ready for next ISA

[sci102] 30/1/2024 14:41

Why they keep mentioning 70% as the target for the trial when it's what this trial is *powered* to show. 27/43 is 63%.

[sci102] 30/1/2024 14:13

So Modi1 is going to first line. That's good. Might reduce the TAM but it is probably the best route forward

[nigelpm] 30/1/2024 10:02

placing at 11p still weighing on price also.

[nigelpm] 30/1/2024 08:45

Very procedural and nothing new from what I could see. Would expect this afternoon's meeting to be similar.

Awaiting more data.

[sci102] 30/1/2024 08:32

Between end of Sept and end of Nov 23 additional patients had been recruited, presumably some of them in Sept-Oct so I hope there is something new in the pres.

[miavoce] 30/1/2024 08:25

Yes, hopefully not too long before another update.

[rogerbridge] 30/1/2024 08:23

Can’t wait for the meeting this afternoon.

[sci102] 30/1/2024 08:22

Therefore we should have an update with additional patients

[miavoce] 30/1/2024 08:02

As the period end was 31st Oct the latest SCOPE updates, referred to in the RNS, were post period.

[marcusl2] 30/1/2024 07:48

Looking good.

Safe and well tolerated.

SCOPE trial with 85% ORR reported from the first 13 patients with unresectable melanoma,One patient achieved a complete response

Modi-1 (ModiFY trial)

SIMILAR TO SCIB1
monotherapy in metastatic disease(spread to a different part of your body part than where it started), one patient achieved a partial response and 60% of patients showed stable disease in response to Modi-1 monotherapy.

Modi-1 to be assessed in renal cell carcinoma in combination with double CPI therapy in the ModiFY study pending protocol amendment by the MHRA.

(If that can achieve good results!! PLus eventually permission to treat Ovarian with CPIs)


GlyMab® and AvidiMab® platforms provide potential out licensing opportunities with ACTIVE DISCUSSIONS ongoing with pharmaceutical and biotech companies.

[sci102] 30/1/2024 07:48

They do mention "including post period" in the RNS though

[chillpill] 30/1/2024 07:46

Not surprising.

Results are results- backward looking.

Any new data would come as a separate release.